Eli Lilly Acquires CrossBridge Bio for Up to $300 Million to Advance Dual-Payload ADC Technology
核心洞察
Eli Lilly has entered a definitive agreement to acquire Houston-based CrossBridge Bio (搜索) for up to $300 million in cash to gain access to next-generation dual-payload antibody-drug conjugate technology.
CrossBridge Bio (搜索)'s lead candidate CBB-120 is a TROP2 (搜索)-targeting dual-payload ADC combining TOP1 (搜索) and ATR inhibitors, designed to enhance therapeutic index and generate more durable responses than current TROP2-targeting ADCs.
The acquisition provides Lilly with innovative dual-payload ADC platform capabilities that could be transformative in oncology, with CBB-120's IND application anticipated in 2026.
Eli Lilly and Company has announced a definitive agreement to acquire CrossBridge Bio (搜索), Inc., a Houston-based biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs), for up to $300 million in cash. The acquisition provides Lilly with access to innovative dual-payload ADC technology that could transform oncology treatment approaches.
Dual-Payload ADC Technology Platform
CrossBridge Bio (搜索) is pioneering dual-payload ADC technology that delivers two toxic warheads to tumors instead of one, representing an advancement over current single-payload approaches. The company's platform was originally developed by Dr. Kyoji Tsuchikama at the University of Texas Health Science Center at Houston (UTHealth Houston) and has been advanced since the company's founding in 2023.
The dual-payload approach aims to address key limitations of current ADC therapies by enhancing the therapeutic index and generating more durable responses while overcoming treatment resistance mechanisms that can limit the effectiveness of existing therapies.
Lead Candidate CBB-120
CrossBridge Bio (搜索)'s lead asset, CBB-120, is a TROP2 (搜索)-targeting dual-payload ADC that combines a topoisomerase I (搜索) (TOP1 (搜索)) inhibitor and an ATR inhibitor. The company believes CBB-120 represents a potential best-in-class advancement over existing TROP2-targeting ADCs such as Datopotamab deruxtecan (Datroway) and Sacituzumab govitecan (Trodelvy).
According to CrossBridge Bio (搜索), CBB-120 is designed to have a wider therapeutic index compared to current TROP2 (搜索)-directed ADCs, potentially allowing for safer and more effective dosing. The dual-payload design is also intended to generate longer-lasting responses and better overcome treatment resistance mechanisms that can limit the durability of current therapies.
The U.S. Food and Drug Administration Investigational New Drug application for CBB-120 is anticipated in 2026, marking the candidate's expected entry into clinical testing.
Strategic Rationale and Market Context
The acquisition reflects the growing industry focus on advanced ADC technologies, with over 20 ADCs currently available to treat various tumor types including breast, lung, and bladder cancers. These therapies have become a pillar of cancer care by precisely delivering toxic payloads to malignant cells while sparing healthy tissue.
"We look forward to seeing how Lilly advances our new generation of dual-payload antibody-drug conjugates, including CBB-120, with the potential to meaningfully improve outcomes for patients with limited treatment options," said Dr. Michael Torres, Co-Founder and CEO of CrossBridge Bio (搜索). "At CrossBridge Bio, we believe our dual-payload ADC platform is uniquely positioned to be transformative in oncology."
Torres emphasized the rapid progress the company has made since its founding, stating: "I'm proud of how well our team has executed and advanced our platform in such a short time since the company's founding. By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach."
Financial Terms and Support
Under the terms of the agreement, CrossBridge Bio (搜索) shareholders could receive up to $300 million in cash, which includes an upfront payment and a subsequent payment contingent upon achieving a specified development milestone. The deal structure reflects confidence in the platform's potential while tying a portion of the payout to developmental progress.
CrossBridge Bio (搜索) has been supported by a syndicate of investors including the Texas Medical Center (TMC) Venture Fund and CE-Ventures (搜索), with participation from Alexandria Venture Investments (搜索), Portal Innovations (搜索), and Linden Lake Labs (搜索). The company has also received non-dilutive funding from the Cancer Prevention and Research Institute of Texas (搜索) (CPRIT).
The acquisition represents Lilly's continued strategy of using dealmaking to strengthen its oncology portfolio, particularly in the rapidly evolving ADC space where technological advances are driving new therapeutic possibilities for cancer patients.